SLC5A2 and heart failure: Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) was the first study involving the use of SGLT2 inhibitors in symptomatic patients with HFrEF to evaluate the effect of dapagliflozin on the outcome of worsening HF, hospitalization for HF, or CV death [11].